Literature DB >> 10330269

Binding of random copolymers of three amino acids to class II MHC molecules.

M Fridkis-Hareli1, R Aharoni, D Teitelbaum, R Arnon, M Sela, J L Strominger.   

Abstract

Copolymer 1 [Cop 1, poly(Y,E,A,K)] is a random synthetic amino acid copolymer of L-tyrosine, L-glutamic acid, L-alanine and L-lysine, effective both in suppression of experimental allergic encephalomyelitis and in the treatment of relapsing forms of multiple sclerosis. Cop 1 binds promiscuously and very efficiently to purified human HLA-DR molecules within the peptide-binding groove. In the present study the binding of copolymers composed of three of the four amino acids found in poly(Y,E,A,K) to purified class II MHC molecules was examined. Poly(Y,A,K) and poly(Y,E,A,K) bound to purified human HLA-DR1 or -DR4 molecules with affinity higher than poly(Y,E,A), poly(E,A,K) or poly(Y,E,K), whereas poly(Y,E,A,K) and poly(E,A,K) were the better binders of HLA-DR2 molecules. On the other hand, poly(Y,E,A) and poly(Y,A,K) inhibited the binding of biotinylated poly(Y,E,A,K) to these molecules 10-fold more efficiently than poly(Y,E,K). Finally, poly(Y,E,A), poly(Y,A,K) and poly(E,A,K) were cross-reactive with poly(Y,E,A,K) using YEAK-specific T cell lines and clones of mouse or human origin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10330269     DOI: 10.1093/intimm/11.5.635

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  3 in total

1.  T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies.

Authors:  J Kipnis; E Yoles; Z Porat; A Cohen; F Mor; M Sela; I R Cohen; M Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 2.  Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?

Authors:  Babak Jalilian; Halldór Bjarki Einarsson; Thomas Vorup-Jensen
Journal:  Int J Mol Sci       Date:  2012-11-09       Impact factor: 5.923

Review 3.  Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

Authors:  Masha Fridkis-Hareli
Journal:  Clin Dev Immunol       Date:  2013-11-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.